Association of exposure to multiple metals with papillary thyroid cancer risk in China

2019 ◽  
Vol 26 (20) ◽  
pp. 20560-20572 ◽  
Author(s):  
Chi Zhang ◽  
Hua-Bing Wu ◽  
Meng-Xia Cheng ◽  
Ling Wang ◽  
Chao-Bing Gao ◽  
...  
2021 ◽  
Author(s):  
Taha Ulutan Kars ◽  
Mustafa Kulaksizoglu ◽  
İbrahim Kılınç

Objective: Thyroid cancer can be detected in 5–10% of patients with thyroid nodules. Management may be a challenge if fine-needle aspiration biopsy yields Bethesda III findings. Most of these cases undergo surgery and are ultimately found benign. Our aim was to evaluate whether serum osteopontin can accurately estimate thyroid cancer risk in cases with cytologically Bethesda III thyroid nodules and, thereby, decrease the number of unnecessary surgical interventions. Design and Methods: We obtained blood samples of cases with repeated cytologically Bethesda III thyroid nodules before surgery, and followed up the pathology results after thyroidectomy. We evaluated serum osteopontin from 36 patients with papillary thyroid cancer and compared them with 40 benign cases. Results: Serum osteopontin levels in patients with papillary thyroid cancer are significantly higher than in benign cases (mean serum osteopontin: 10.48 ± 3.51 ng/mL vs 6.14 ± 2.29 ng/mL, p<0.001). The area under the receiver operating characteristics curve was 0.851, suggesting that serum osteopontin could have considerable discriminative performance. Conclusions: In our preliminary study, high serum osteopontin levels can predict the risk of papillary thyroid cancer in thyroid nodules with Bethesda III cytology. Further studies are necessary to confirm these findings.


2012 ◽  
Vol 21 (12) ◽  
pp. 2268-2271 ◽  
Author(s):  
Cari M. Kitahara ◽  
Gila Neta ◽  
Ruth M. Pfeiffer ◽  
Deukwoo Kwon ◽  
Li Xu ◽  
...  

Thyroid ◽  
2012 ◽  
Vol 22 (2) ◽  
pp. 151-156 ◽  
Author(s):  
Sara J. Schonfeld ◽  
Gila Neta ◽  
Erich M. Sturgis ◽  
Ruth M. Pfeiffer ◽  
Amy A. Hutchinson ◽  
...  

2016 ◽  
Vol 86 (5-6) ◽  
pp. 189-197
Author(s):  
Christopher Kim ◽  
Huang Huang ◽  
Nan Zhao ◽  
Catherine C. Lerro ◽  
Min Dai ◽  
...  

Abstract. Certain dietary supplements have been reported to increase the risk of some cancers. Over half of the US population regularly uses dietary supplements. Thyroid cancer incidence has increased over the past several decades. However, few studies have investigated the association between dietary supplements and thyroid cancer. Thus, it is essential to clarify any association between dietary supplements and risk of thyroid cancer. Materials and methods: A population-based case-control study in Connecticut was conducted during 2010–2011 among 462 histologically confi rmed incident thyroid cancer cases and 498 population-based controls. Dietary supplement intake was ascertained through in-person interviews and a food frequency questionnaire. Multivariate unconditional logistic regression models were used to estimate the risk of thyroid cancer and dietary supplement use. Results: Overall, no statistically signifi cant associations were observed between dietary supplementation and thyroid cancer risk. Stratifi ed analyses revealed a suggestive protective effect on risk of papillary microcarcinoma among longterm (> 10 years) use of multivitamins (OR = 0.59, 95 % CI: 0.33, 1.04) and calcium supplementation (OR = 0.45, 95 % CI: 0.22, 0.93). An increased risk of large papillary thyroid cancers (tumor size > 1 cm) was observed among short-term (< 5 years) users of calcium supplements (OR = 2.24, 95 % CI: 1.30, 3.88). Discussion: No signifi cant associations were observed between supplementation and overall thyroid cancer risk. The different associations between calcium supplements and risk of papillary thyroid cancer by tumor size warrant further investigation.


Sign in / Sign up

Export Citation Format

Share Document